SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years

The goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines. The study includes children aged 12 months to 12 years. Approximately 780 participants will take part in this study. Participants will be randomly assigned to receive either the investigational vaccine (NBP608) or licensed varicella vaccines. Some participants will receive two doses, while others will receive one dose, according to the assigned study group. Participants will: Receive two subcutaneous injections of a study vaccine, administered approximately three months apart (if applicable). Visit the study clinic seven times over approximately 15 months. Receive follow-up phone calls 7 days after each vaccination to monitor for safety.

NCT Number	NCT07415252
Lead Sponsor	SK Bioscience Co., Ltd.
Conditions	Varicella (Chickenpox)
Enrollment	780 participants
Start Date	2026-06-05
Primary Completion	2027-02-13 (estimated)
Study Completion	2028-01-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-15